Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Purchases 20,000 Shares

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera bought 20,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were acquired at an average price of $2.05 per share, with a total value of $41,000.00. Following the completion of the acquisition, the director directly owned 386,904 shares in the company, valued at $793,153.20. This represents a 5.45% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Robert Jr. Baltera also recently made the following trade(s):

• On Tuesday, July 7th, Robert Jr. Baltera purchased 30,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $2.03 per share, for a total transaction of $60,900.00.
• On Thursday, July 2nd, Robert Jr. Baltera purchased 10,000 shares of Palisade Bio stock. The stock was acquired at an average price of $1.98 per share, for a total transaction of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The shares were acquired at an average cost of $1.98 per share, with a total value of $39,600.00.

Palisade Bio Price Performance

Shares of PALI opened at $2.05 on Thursday. Palisade Bio, Inc. has a 1-year low of $0.53 and a 1-year high of $2.86. The stock has a market cap of $355.84 million, a price-to-earnings ratio of -2.03 and a beta of 1.50. The firm has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $1.92.

Palisade Bio (NASDAQ:PALI) last posted its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, equities analysts expect that Palisade Bio, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PALI. Oppenheimer set a $7.00 price target on Palisade Bio in a report on Tuesday, June 30th. Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. Finally, Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Sunday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Palisade Bio presently has an average rating of “Buy” and a consensus target price of $8.83.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PALI. Perceptive Advisors LLC purchased a new stake in Palisade Bio during the fourth quarter valued at about $28,318,000. Commodore Capital LP purchased a new position in shares of Palisade Bio in the 4th quarter worth about $26,896,000. Janus Henderson Group PLC purchased a new position in shares of Palisade Bio in the 4th quarter worth about $24,822,000. RA Capital Management L.P. acquired a new position in shares of Palisade Bio in the 4th quarter valued at about $16,742,000. Finally, Eversept Partners LP acquired a new position in shares of Palisade Bio in the 4th quarter valued at about $12,670,000. 11.79% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Palisade Bio

Here are the key news stories impacting Palisade Bio this week:

• Positive Sentiment: Director Robert Jr. Baltera bought 30,000 shares at about $2.03 per share, following earlier purchases of 20,000 shares and 10,000 shares at $1.98. Repeated insider buying can signal confidence in Palisade Bio’s outlook. SEC filing
• Positive Sentiment: Analysts remain broadly constructive on Palisade Bio, with recent ratings including a “strong-buy” upgrade and multiple buy ratings, plus a consensus price target well above the current trading range. MarketBeat PALI page
• Neutral Sentiment: CEO John David Finley sold 146,798 shares, but the filing says the transaction was to cover tax withholding obligations tied to vesting equity awards, which makes the sale less concerning than a discretionary insider exit. SEC filing
• Neutral Sentiment: Insider Mitchell Lawrence Jones also sold shares for the same tax-withholding reason, adding to the day’s mixed insider activity. SEC filing

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.